KA/EN
Register
Medicines reference
Search
Search
Product

Allerdex

Favourites

Dexamethasone · Nextra Group

1 form: eye drops. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
1 mg/ml (0.1%), Eye drops No label dose in the reference yet - Georgia Yes, human
In force until 10 Oct 2028
Human (Ministry of Health, RAMA)
In the register: ალერდექსი 1 მგ/მლ (0.1%), თვალის წვეთები სუსპენზია 10 მლ
№ რ-039299
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Allerdex 1 mg/ml (0.1%), Eye drops

eye drops suspension 10 ml, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea
6.7/10
Situational / acceptable
vetman assessment

Allerdex

1 mg/ml (0.1%), eye drops suspension 10 ml, human medicine
Assessed clinical scopeDog · Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea · Into the eye
Care settingVeterinarian-directed clinic or home treatment after slit-lamp or magnified examination, fluorescein staining and intraocular-pressure assessment where relevant, with scheduled early recheck and taper based on response
vetman score 6.7/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-039299 · Verified on 16 Oct 2026 Off-label use

A useful potent topical steroid for a diagnosed, noninfectious steroid-responsive eye disease when the cornea is intact. Its value depends on examination rather than brand familiarity: stain before treatment, exclude or control infection, monitor pressure and response, taper longer courses, and stop immediately if pain, discharge or corneal damage emerges.

Regulatory and scientific credibility5.5/10

This exact human 0.1% ophthalmic product has a sourced current Georgian registration and identifiable formulation and manufacturer; exhaustive current checks record no exact EU/EEA, GB or US registration. Veterinary use is off-label, although an EU-authorised dog/cat veterinary dexamethasone eye-drop solution supports the species, route and concentration.

Clinical efficacy8.0/10

Topical 0.1% dexamethasone is a standard, cornea-penetrating veterinary corticosteroid for noninfectious anterior ocular inflammation. Current canine data support improvement in moderate-to-severe follicular conjunctivitis and combination therapy for chronic superficial keratitis, while established use covers anterior uveitis, immune-mediated keratitis and episcleritis; diagnosis and cause-directed therapy determine benefit.

Safety and tolerability6.0/10

Correctly selected use is usually locally tolerable, but corticosteroids delay epithelial healing, increase collagenase activity and can convert an occult abrasion into a melting ulcer. Repeated treatment can increase intraocular pressure, promote infection, cataract and steroid keratopathy, and systemic absorption with cortisol suppression is documented after four-times-daily dosing.

Clinical practicality7.5/10

A standard dropper gives a directly deliverable ocular dose, but the suspension must be shaken thoroughly before every use and ten-millilitre packaging increases post-opening waste for short courses. Frequent initial dosing, atraumatic restraint, avoiding tip contact, separating other drops and scheduled re-examination remain material treatment burdens.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform fluorescein staining before starting and whenever new pain develops. Do not use topical dexamethasone with a corneal abrasion, ulcer, descemetocele, melting ulcer, perforation or unhealed penetrating injury; it delays epithelial repair and can accelerate collagenolysis.
  • Do not use as steroid monotherapy for an undiagnosed red eye or untreated bacterial, fungal, mycobacterial, parasitic or viral ocular infection. Establish and treat the cause; immunosuppression can mask progression and allow rapid loss of corneal integrity.
  • Reassess the diagnosis urgently if blepharospasm, discharge, corneal clouding, focal staining, vision change or worsening redness appears; stop dexamethasone until ulceration and infection have been excluded.
  • Measure intraocular pressure when glaucoma is possible and during repeated or prolonged treatment. Topical dexamethasone can raise pressure, cause glaucoma or cataract and promote steroid keratopathy; monitor the cornea, lens and treatment response rather than renewing indefinitely.
  • Ophthalmic dexamethasone is systemically absorbed. Four-times-daily dosing for 14 days suppressed cortisol in healthy dogs; use the lowest effective frequency, consider nasolacrimal occlusion, and review diabetes, hyperadrenocorticism, infection risk and concurrent systemic corticosteroids.
  • Use an indication-appropriate initial frequency and recheck early; severe anterior inflammation may need frequent treatment, whereas chronic immune-mediated disease requires response-guided tapering. Do not stop a prolonged course abruptly or continue unchanged without confirming control.
  • This score covers diagnosed steroid-responsive ocular inflammation as a clinical class, not every human-label indication and not posterior-segment disease that topical drops cannot adequately reach. Lack of response should trigger diagnostic reassessment, not automatic dose escalation.
  • Avoid touching the dropper tip to the eye, lashes or skin; use one bottle per patient where contamination is plausible and separate different eye drops by at least several minutes. Shake suspension products thoroughly before every dose.
  • Safety of these exact human products in pregnant or lactating dogs and cats has not been established. Use only after a documented veterinary benefit-risk assessment, especially for prolonged or bilateral treatment that increases systemic exposure.
Assessment sources
  1. Dexamethasone eye-drop market audit2026
  2. Maxidex 0.1% SmPC2026
  3. Dexavet veterinary authorisation2026
  4. MSD ophthalmic steroids2026
  5. Canine and feline uveitis review2002
  6. Canine ophthalmic steroid absorption2022
  7. Canine follicular conjunctivitis2023
  8. Canine CSK dexamethasone study2021
  9. ABCD feline herpesvirus guideline2009
  10. Canine steroid keratopathy2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea
6.1/10
Situational / acceptable
vetman assessment

Allerdex

1 mg/ml (0.1%), eye drops suspension 10 ml, human medicine
Assessed clinical scopeCat · Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea · Into the eye
Care settingVeterinarian-directed clinic or home treatment after slit-lamp or magnified examination, fluorescein staining and intraocular-pressure assessment where relevant, with scheduled early recheck and taper based on response
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-039299 · Verified on 16 Oct 2026 Off-label use

A useful potent topical steroid for a diagnosed, noninfectious steroid-responsive eye disease when the cornea is intact. Its value depends on examination rather than brand familiarity: stain before treatment, exclude or control infection, monitor pressure and response, taper longer courses, and stop immediately if pain, discharge or corneal damage emerges.

Regulatory and scientific credibility5.5/10

This exact human 0.1% ophthalmic product has a sourced current Georgian registration and identifiable formulation and manufacturer; exhaustive current checks record no exact EU/EEA, GB or US registration. Veterinary use is off-label, although an EU-authorised dog/cat veterinary dexamethasone eye-drop solution supports the species, route and concentration.

Clinical efficacy7.0/10

Topical 0.1% dexamethasone is an established cornea-penetrating corticosteroid for selected noninfectious feline anterior ocular inflammation, including immune-mediated keratitis, conjunctival disease and anterior uveitis. Direct controlled feline efficacy data are limited, and latent FHV-1 or infectious disease can make an apparently inflammatory presentation steroid-inappropriate.

Safety and tolerability5.0/10

Corneal ulceration or untreated infection creates a serious local hazard, and feline herpesvirus may reactivate with topical steroid exposure, causing ulceration or sequestrum. Longer treatment can increase intraocular pressure, delay healing, promote infection or cataract and cause systemic glucocorticoid exposure; feline product-specific safety data are limited.

Clinical practicality7.5/10

A standard dropper gives a directly deliverable ocular dose, but the suspension must be shaken thoroughly before every use and ten-millilitre packaging increases post-opening waste for short courses. Frequent initial dosing, atraumatic restraint, avoiding tip contact, separating other drops and scheduled re-examination remain material treatment burdens.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform fluorescein staining before starting and whenever new pain develops. Do not use topical dexamethasone with a corneal abrasion, ulcer, descemetocele, melting ulcer, perforation or unhealed penetrating injury; it delays epithelial repair and can accelerate collagenolysis.
  • Do not use as steroid monotherapy for an undiagnosed red eye or untreated bacterial, fungal, mycobacterial, parasitic or viral ocular infection. Establish and treat the cause; immunosuppression can mask progression and allow rapid loss of corneal integrity.
  • Topical corticosteroids can reactivate latent feline herpesvirus and precipitate ulcerative keratitis or corneal sequestrum. In a cat with compatible history or dendritic/geographic disease, stop steroid treatment and investigate/treat FHV-associated disease before considering further immunosuppression.
  • Measure intraocular pressure when glaucoma is possible and during repeated or prolonged treatment. Topical dexamethasone can raise pressure, cause glaucoma or cataract and promote steroid keratopathy; monitor the cornea, lens and treatment response rather than renewing indefinitely.
  • Ophthalmic dexamethasone is systemically absorbed. Four-times-daily dosing for 14 days suppressed cortisol in healthy dogs; use the lowest effective frequency, consider nasolacrimal occlusion, and review diabetes, hyperadrenocorticism, infection risk and concurrent systemic corticosteroids.
  • Use an indication-appropriate initial frequency and recheck early; severe anterior inflammation may need frequent treatment, whereas chronic immune-mediated disease requires response-guided tapering. Do not stop a prolonged course abruptly or continue unchanged without confirming control.
  • This score covers diagnosed steroid-responsive ocular inflammation as a clinical class, not every human-label indication and not posterior-segment disease that topical drops cannot adequately reach. Lack of response should trigger diagnostic reassessment, not automatic dose escalation.
  • Avoid touching the dropper tip to the eye, lashes or skin; use one bottle per patient where contamination is plausible and separate different eye drops by at least several minutes. Shake suspension products thoroughly before every dose.
  • Safety of these exact human products in pregnant or lactating dogs and cats has not been established. Use only after a documented veterinary benefit-risk assessment, especially for prolonged or bilateral treatment that increases systemic exposure.
Assessment sources
  1. Dexamethasone eye-drop market audit2026
  2. Maxidex 0.1% SmPC2026
  3. Dexavet veterinary authorisation2026
  4. MSD ophthalmic steroids2026
  5. Canine and feline uveitis review2002
  6. Canine ophthalmic steroid absorption2022
  7. Canine follicular conjunctivitis2023
  8. Canine CSK dexamethasone study2021
  9. ABCD feline herpesvirus guideline2009
  10. Canine steroid keratopathy2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dexamethasone1 mg/ml
Formulation Type
Eye drops
Administration route
Into the eye
Manufacturer
Nextra Group
Registration
Georgia Yes, human
In force until 10 Oct 2028
Human (Ministry of Health, RAMA)
In the register: ალერდექსი 1 მგ/მლ (0.1%), თვალის წვეთები სუსპენზია 10 მლ
№ რ-039299
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Dexamethasone
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.05–0.2 mg/kg Dog Inflammation By mouth once daily in the morning
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.1 mg/kg Dog, Cat Allergic Reaction Intramuscular as needed
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexadreson 2 mg/ml Solution for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.05–0.2 mg/kg Cat Inflammation By mouth once daily in the evening
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical
    Do not use corticosteroids, topically or systemically, while a corneal ulcer is present. They slow healing of the corneal epithelium and can increase collagenase activity, which may turn the ulcer into a melting ulcer.
    Sources: MSD Vet Manual
  • Critical
    Do not use dexamethasone in animals with diabetes mellitus or hyperadrenocorticism unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with diabetes mellitus or hyperadrenocorticism.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with osteoporosis because corticosteroids increase protein catabolism and can reduce bone mass.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with cardiac or renal dysfunction, including congestive heart failure, unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    the product should not be used in animals suffering from diabetes, chronic nephritis, renal disease, congestive heart failure, osteoporosis and in viral infections during the viraemic stage
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with cardiac or renal dysfunction.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with gastro-intestinal ulceration.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with glaucoma.
    Sources: VMD SPC · VMD
  • Critical
    Do not use systemic dexamethasone in animals with burns unless specifically indicated and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone during pregnancy because early exposure can cause fetal abnormalities and late exposure can induce abortion or premature parturition.
    Sources: VMD SPC · VMD
  • Critical
    Known hypersensitivity to dexamethasone, another corticosteroid, or any excipient is a contraindication.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with viral or mycotic infections.
    Sources: VMD SPC · VMD
  • Warning
    Use with particular caution in an immunocompromised patient because corticosteroids delay wound healing and can exacerbate an existing infection.
    Sources: VMD SPC · VMD
  • Warning
    Corticoids such as dexamethasone should be used with caution in patients with hypertension.
    Sources: VMD SPC · VMD
  • Warning
    Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian.
    Sources: VMD SPC · VMD
  • Warning
    Do not use concomitantly with attenuated alive vaccine dexamethasone should not be used in combination with vaccines or within two weeks after vaccination
    Sources: VMD SPC · VMD
  • Caution
    Due to the long duration of effect of dexamethasone alternate day therapy is not an adequate way to allow the hypothalamic-pituitary-adrenal axis to recover.
    Sources: VMD SPC · VMD
  • Caution
    Use cautiously in geriatric or debilitated animals because corticosteroids increase protein catabolism. Prolonged treatment can cause cushingoid changes, including fat redistribution, muscle weakness and atrophy, and osteoporosis.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Contraindicated Robenacoxib + Dexamethasone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Meloxicam + Dexamethasone
    The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration.
    Recommendation: Avoid concurrent administration. Observe an appropriate washout period when switching. If both are essential, provide gastroprotection and monitor gastrointestinal signs closely.
    Sources: VMD SPC · VMD
  • Major warning Carprofen + Dexamethasone
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA
  • Major warning Dexamethasone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Dexamethasone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Minor warning Furosemide + Dexamethasone
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium. Hypokalaemia also increases cardiac glycoside toxicity.
    Sources: VMD SPC · VMD
  • Minor warning Dexamethasone + Torasemide
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (31 more) Hide additional products

Same active ingredients 9

Same therapeutic group 22

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗